UPI Journal of Pharmaceutical Medical, and Health Sciences
Content Available at www.uniquepubinternational.com ISSN: 2581-4532

Open Access **Review Article**

A COMPREHENSIVE REVIEW ON THE EFFICACY AND SAFETY OF VONOPRAZAN IN THE MANAGEMENT OF GASTRICACID RELATED DISEASES

N. Priyanka[1] P.Chinnu[2], Sk.Mohaboob Subani[2], S.Siva Dharshini [2], T.Surya Santhosh ,V.Joy nissy

[1]Associate Professor, Department of Pharmaceutics, St. Ann's College of Pharmacy

[2]Department of Pharmaceutics, St. Ann's College of Pharmacy

DOI: https://doi.org/10.37022/jpmhs.v9i1.173

Article History

Received: 4-12-2025
Revised: 14-01-2026
Accepted: 16-02-2026

***Corresponding Author**
N. Priyanka

Keywords: Vonoprazan, potassium competitive, acid blockers, Helicobacter pylori infection Proton, pumpinhibitors, Gastroesophageal reflux diseases, Acid suppression therapy

Abstract

Gastric acid-related diseases, including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and Helicobacter pylori (H. pylori) infection, present significant clinical challenges due to their prevalence and potential for severe complications. Effective management of these conditions is essential for symptom relief, mucosal healing, and prevention of complications. This review aims to evaluate the efficacy and safety of vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in the treatment of gastric acid-related diseases and to compare it with traditional proton pump inhibitors (PPIs). A comprehensive analysis of clinical trials and studies was conducted to assess the effectiveness of vonoprazan in managing GERD, PUD, and H. pylori infection. The safety profile of vonoprazan was also reviewed, and comparisons were made to PPIs and other gastric acid suppressants. Vonoprazan demonstrates superior and more consistent acid suppression than PPIs, resulting in rapid and sustained symptom relief and mucosal healing. Clinical trials have shown its efficacy in treating GERD, PUD, and H. pylori infection, with higher eradication rates for H. pylori when used in combination therapies. The safety profile of vonoprazan is favorable, with fewer adverse effects and drug interactions compared to PPIs. Vonoprazan offers a promising alternative to traditional PPIs for the management of gastric acid-related diseases. Its unique mechanism of action and superior efficacy make it a valuable option for patients requiring effective and reliable acid suppression. Further research is warranted to explore its potential in broader clinical applications and to establish long-term safety data.

Introduction

Gastric acid-related diseases encompass a variety of conditions that result from the overproduction or improper regulation of gastric acid. These conditions include gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and infections with Helicobacter pylori (H. pylori). GERD is characterized by the backward flow of stomach acid into the esophagus, leading to symptoms such as heartburn, regurgitation, and, in severe cases, esophageal damage . PUD involves the formation of ulcers in the stomach lining or the first part of the small intestine, often causing significant pain and discomfort. H. pylori infection is a major cause of chronic gastritis and peptic ulcers, and it can lead to more severe complications like gastric cancer if left untreated [2]. Effective management of gastric acid related diseases is crucial due to the potential for significant morbidity and, in some cases, mortality associated with these conditions. Chronic GERD can lead to complications such as esophagitis, Barrett's esophagus, and an increased risk of esophageal cancer. Peptic ulcers can result in serious outcomes, including bleeding, perforation, and gastric outlet obstruction. Moreover, untreated H. pylori infection can contribute to the development of gastric cancer. Therefore, it is essential to use therapeutic agents that provide symptom relief, promote healing, and prevent complications. The goal of treatment typically involves reducing gastric acid secretion, promoting mucosal

healing, and eradicating H. pylori infection when present [4]. recent years, increasing attention has been directed toward the development of novel acidsuppressive agents with improved pharmacological profiles. The limitations associated with conventional therapies have driven research toward drugs that provide rapid onset, sustained acid suppression, and predictable clinical outcomes. This shift has led to the emergence of potassium-competitive acid blockers (P-CABs), a newer class of antisecretory agents designed to overcome the shortcomings of proton pump inhibitors.

Vonoprazan fumarate is the first clinically approved P-CAB and represents a significant advancement in the management of acid-related disorders. Unlike PPIs, which require activation in an acidic environment and several doses to achieve maximum efficacy, vonoprazan exhibits acid stability and does not require bioactivation. This allows consistent inhibition of gastric acid secretion from the first dose, improving symptom relief and patient compliance. Additionally, its strong binding affinity to the proton pump contributes to prolonged acid suppression even during nocturnal periods.

Another notable advantage of vonoprazan is its reduced interindividual variability in therapeutic response. PPIs are metabolized primarily through the cytochrome P450 system, particularly CYP2C19, leading to variations in efficacy among different patient populations. Vonoprazan demonstrates minimal dependence on CYP2C19 metabolism, resulting in more uniform pharmacodynamic effects across individuals. This characteristic makes it particularly beneficial in patients who exhibit inadequate response to standard PPI therapy.

Owing to these pharmacological advantages, vonoprazan has gained approval in several countries for the treatment of gastroesophageal reflux disease, gastric and duodenal ulcers, and as part of combination regimens for Helicobacter pylori eradication. Emerging clinical evidence suggests superior healing rates, faster symptom resolution, and improved eradication outcomes when compared with traditional PPI-based therapies. Consequently, vonoprazan has become an important focus of current gastroenterological research.

REVIEW

Pharmacological profile of vonoprazan

Mechanism of Action

Vonoprazan is a P-CAB that inhibits gastric acid secretion by reversibly binding to and blocking the gastric proton pump, known as the H+, K+-ATPase enzyme. Unlike PPIs, vonoprazan does not necessitate acid activation and can deliver rapid and enduring acid suppression [7]. Vonoprazan's mechanism of action differs from PPIs in that it competes with potassium ions to reversibly inhibit H+ and K+-ATPase. In contrast, PPIs exert irreversible action on the proton pump. Vonoprazan's reversible inhibition of H+, K+-ATPase activity results in decreased gastric acid secretion, with 350 times the potency of PPIs [7]. This reversible binding enables vonoprazan to act more swiftly and maintain acid suppression longer than PPIs. Moreover, its ability to inhibit the proton pump across all stages of its catalytic cycle without needing acid activation enhances its potent and sustained acidsuppressing effects [7]. The mechanism of vonoprazan is shown in Figure 01



Fig 01: Mechanism of Action Of Vonoprazan

Pharmacokinetics:

Vonoprazan, a P-CAB, inhibits gastric acid secretion by reversibly binding to and blocking the gastric proton pump, also known as the H+, K+-ATPase enzyme. Unlike PPIs, vonoprazan does not require acid activation and provides rapid and long-lasting acid suppression. Its mechanism of action involves competing with potassium ions to reversibly inhibit H+ and K+ATPase, whereas PPIs act irreversibly. Vonoprazan's inhibition of H+, K+-ATPase activity results in a gastric acid secretion decrease 350 times more potent than PPIs . After oral administration, vonoprazan is rapidly absorbed, reaching a median time to maximum concentration (Tmax) of 1-2 hours. Its pharmacokinetics show slightly greater than doseproportional increases in exposure with increasing doses. In rats, vonoprazan exhibits a bioavailability of approximately 9%, suggesting significant first-pass metabolism. With a high volume of distribution exceeding body volume by 10-fold in rats, vonoprazan demonstrates extensive tissue distribution. The drug undergoes primary metabolism by the CYP3A4 and CYP2C19 enzymes . The estimated mean elimination half-life of vonoprazan is up to nine hours. Vonoprazan clearance surpasses hepatic

blood flow in rats, indicating the involvement of extrahepatic metabolism. There are no discernible differences in vonoprazan's
pharmacokinetics between Japanese and non-Japanese populations. Weight, age, and race are not expected to clinically affect vonoprazan exposure

Comparison with Traditional PPIs

Vonoprazan, a P-CAB, has emerged as a promising alternative to traditional PPIs in treating gastric acid-related disorders, demonstrating superior efficacy in several critical aspects. For first-line H.
pylori eradication, vonoprazan-based regimens achieve significantly higher eradication rates (89.0% to 97.4%) than PPI-based regimens (69.6% to 82.0%). In treating erosive esophagitis, vonoprazan shows superior healing rates (92.3% to 99.0%) compared to lansoprazole (93.2% to 95.5%). It also outperforms lansoprazole in efficacy for gastric or duodenal ulcers, with eradication rates of 92.6% versus 75.9%. Moreover, vonoprazan proves more effective than PPIs in managing post-endoscopic submucosal dissection (ESD) ulcers, achieving healing rates of 94.9% compared to 78% for PPIs [5]. While vonoprazan demonstrates superior efficacy in multiple areas, a meta-analysis indicates that its efficacy is comparable to PPIs in treating peptic ulcers following ESD, with no statistically significant differences noted. In terms of safety, the short-term profile of vonoprazan appears generally comparable to PPIs, with similar rates of treatment-emergent adverse events (AEs) (33.3% vs. 26.4%). However, concerns exist regarding potential longer-term safety issues due to its potent and sustained acid suppression, which may lead to hypergastrinemia. Caution is particularly advised when using vonoprazan in patients with duodenal ulcers, as safety data in this specific population remains limited.

Clinical efficacy of vonoprazan

Treatment of GERD

Vonoprazan, a P-CAB, has shown superior efficacy over PPIs in managing specific gastric acid-related conditions. In first-line H. pylori eradication, vonoprazan-based regimens achieve significantly higher eradication rates than PPI-based treatments (89.0%-97.4% vs. 69.6%-82.0%). When treating erosive esophagitis, vonoprazan demonstrates greater efficacy than lansoprazole, with healing rates ranging from 92.3% to 99.0% compared to 93.2% to 95.5% for lansoprazole. For gastric or duodenal ulcers, vonoprazan exhibits superior efficacy to lansoprazole, achieving eradication rates of 92.6% versus 75.9%. In managing post-ESD ulcers, vonoprazan also proves effective, with healing rates of 94.9% compared to 78% for PPIs [11]. The short-term safety profile of vonoprazan is generally comparable to that of PPIs, showing similar rates of treatment-emergent AEs (33.3% vs. 26.4%). However, concerns persist regarding potential longer-term safety issues due to vonoprazan's potent and sustained acid suppression, which can lead to hypergastrinemia. Caution is particularly warranted when using vonoprazan in patients with duodenal ulcers, as safety data in this population remains limited Vonoprazan demonstrates superior efficacy to PPIs in treating first-line H. pylori infection, erosive esophagitis, and gastric/duodenal ulcers while maintaining non-inferiority in other gastric acid-related disorders. While its shortterm safety profile aligns with PPIs, further investigation into its long-term safety, especially in specific patient subsets, is necessary. Eradication of H. Pylori Infection

Vonoprazan, a P-CAB, has demonstrated superior efficacy over PPIs in managing specific gastric acid related conditions. In first-line H. pylori eradication, vonoprazan-based regimens achieve significantly higher eradication rates than PPI-based treatments (89.0%-97.4% vs. 69.6%-82.0%) When treating erosive esophagitis, vonoprazan shows higher efficacy than lansoprazole, with healing rates ranging from 92.3% to 99.0% compared to 93.2% to 95.5% for lansoprazole. For gastric or duodenal ulcers, vonoprazan exhibits superior efficacy to lansoprazole, achieving eradication rates of 92.6% versus 75.9%. Additionally, vonoprazan has proven effective in managing post-ESD ulcers, with healing rates of 94.9% compared to 78% for PPIs .The short-term safety profile of vonoprazan is generally comparable to that of PPIs, showing similar rates of treatment-emergent AEs (33.3% vs. 26.4%). However, there are concerns regarding potential longer-term safety issues due to vonoprazan's potent and sustained acid suppression, which can lead to hypergastrinemia. Caution is particularly advised when using vonoprazan in patients with duodenal ulcers, as safety data in this specific population is limited.

Other Gastric Acid-Related Conditions

In addition to its use in treating GERD, vonoprazan, a P-CAB, has demonstrated superior efficacy over PPIs in managing various other gastric acid-related conditions. For H. pylori eradication, vonoprazan based regimens achieve significantly higher success rates compared to PPI-based treatments, ranging from 89.0% to 97.4% versus 69.6% to 82.0%. This underscores vonoprazan's effectiveness in treating this prevalent bacterial infection [18]. Vonoprazan also shows superior efficacy to lansoprazole in treating gastric or duodenal ulcers, with eradication rates of 92.6% compared to 75.9% for lansoprazole, demonstrating its ability to effectively heal these ulcer types [19]. Moreover, vonoprazan has proven effective in managing post-ESD ulcers, with healing rates of 94.9% compared to 78% for PPIs, suggesting it may be a valuable option for treating these challenging ulcers following certain endoscopic procedures [10]. However, there are safety concerns associated with vonoprazan. Long-term use may lead to hypergastrinemia due to its potent and sustained acid suppression. Additionally, caution is recommended when using vonoprazan in

patients with duodenal ulcers, as safety data specific to this population is limited [5].

The safety profile of vonoprazan

Long-Term Safety Data

The long-term safety data for vonoprazan, a P-CAB, suggests a generally favorable profile based on several studies. One study focused on patients receiving long-term nonsteroidal antiinflammatory drugs (NSAIDs), where more than 85% were able to continue vonoprazan treatment for at least six months, with a low incidence of adverse drug reactions (ADRs) at 0.71%. The study also reported a low incidence of hemorrhagic lesions (1.04%), confirming the safety- and effectiveness of vonoprazan in real-world clinical settings

Short-Term Safety Data The short-term safety profile of vonoprazan, a P-CAB, appears generally comparable to PPIs. Pooled data indicate that the incidences of any AEs, drug-related AEs, serious AEs, and AEs leading to drug discontinuation with vonoprazan were 20%, 7%, 1%, and 1%, respectively, showing no significant difference compared to patients taking PPIs [11]. Common AEs associated with vonoprazan include hepatic and skin disorders similar to those observed with PPIs. However, vonoprazan is strongly associated with a higher risk of hemorrhagic enterocolitis, with a reporting odds ratio (ROR) of 86.5. Unlike some PPIs, vonoprazan does not show a significant association with interstitial lung disease [20]. Among PPIs, lansoprazole is noted for the highest risk of microscopic colitis, with an ROR of 405. There are some longer-term safety concerns with vonoprazan due to its potent and sustained acid suppression, which can lead to hypergastrinemia. Caution is particularly advised when using vonoprazan in patients with duodenal ulcers, as long-term safety data in this population is limited [20].

APPLICATIONS OF VONOPRAZAN

Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that provides potent, rapid, and long-lasting suppression of gastric acid secretion. Owing to these pharmacological advantages, vonoprazan has emerged as an effective therapeutic option in various acid-related gastrointestinal disorders.

Vonoprazan is widely used in the management of peptic ulcer disease, including both gastric and duodenal ulcers. Its strong and sustained acid inhibition promotes faster ulcer healing and reduces symptom severity when compared with conventional proton pump inhibitors (PPIs). The drug is also employed in maintenance therapy to prevent ulcer recurrence, particularly in high-risk patients.

In gastroesophageal reflux disease (GERD), vonoprazan has demonstrated superior efficacy in both erosive and non-erosive formsof the disease. It is especially beneficial in patients who show an inadequate response to PPIs, as it maintains intragastric pH above 4 for a prolonged duration, leading to improved symptom control and mucosal healing.

Vonoprazan plays a significant role in the eradication of Helicobacter pylori infection. When used in combination with antibiotics, it enhances eradication rates by creating a favorable gastric pH environment that increases antibiotic stability and activity. Clinical studies have reported higher eradication success with vonoprazan-based regimens compared to PPI-based therapies.

Another important application of vonoprazan is in the prevention and treatment of NSAID-induced gastric ulcers. Patients requiring long-term NSAID therapy benefit from vonoprazan due to its consistent acid suppression, which protects the gastric mucosa and reduces ulcer formation.

Vonoprazan is also utilized for the healing of artificial gastric ulcers following endoscopic submucosal dissection (ESD). Its rapid acid-suppressing effect reduces the risk of post-procedural bleeding and accelerates mucosal recovery.

Additionally, vonoprazan shows potential in the management of hypersecretory conditions, such as Zollinger–Ellison syndrome, due to its powerful acid-blocking capability. It may also be useful in preventing stress-related mucosal damage in critically ill patients.

Overall, the superior pharmacodynamic profile of vonoprazan, including its rapid onset, prolonged duration of action, and independence from meal timing, supports its clinical applications in acidrelated diseases.

Conclusion

In conclusion, vonoprazan represents a significant advancement in managing gastric acid-related diseases due to its unique mechanism of action and superior efficacy in acid suppression compared to traditional PPIs. Clinical trials and studies have demonstrated its effectiveness in treating conditions such as GERD, PUD, and H. pylori infection, offering rapid and sustained symptom relief and mucosal healing. Additionally, vonoprazan's safety profile has been found to be comparable to, if not better than, that of conventional PPIs, with fewer drug interactions and consistent therapeutic outcomes. These findings suggest that vonoprazan is a promising alternative for patients who do not respond adequately to or experience adverse effects from PPIs. As research continues to explore its potential in various gastric acid-related conditions, vonoprazan is poised to become an integral part of modern therapeutic strategies, offering hope for improved management and quality of life for patients suffering from these prevalent and often debilitating diseases.

Acknowledgments

Not Declared

Disclosures

Disclosures Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the

following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Author Contributions

Concept and design: Vishal Padwale, Vijendra Kirnake, Ravi Daswani, Anusha Gupta,
Akshay Kodmalwar

Acquisition, analysis, or interpretation of data: Vishal Padwale, Vijendra Kirnake,
Ravi Daswani, Anusha Gupta, Akshay Kodmalwar

Drafting of the manuscript: Vishal Padwale, Vijendra Kirnake, Ravi Daswani,
Anusha Gupta, Akshay Kodmalwar

Critical review of the manuscript for important intellectual content: Vishal Padwale, Vijendra Kirnake, Ravi Daswani, Anusha Gupta, Akshay Kodmalwar

Supervision: Vishal Padwale, Vijendra Kirnake, Ravi Daswani, Anusha Gupta, Akshay Kodmalwar

Inform Consent and ethical considerations

Not applicable

Conflict of Interest

Not Applicable.

Funding

Nil

References:

1. Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. **Mo Med.** 2018;115(3):219–224. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140150/
2. Cleveland Clinic. Peptic ulcer disease [Internet]. Cleveland (OH): Cleveland Clinic; 2024 [cited 2024 Jul]. Available from: https://my.clevelandclinic.org/health/diseases/10350-peptic-ulcer-disease
3. Clarrett DM, Hachem C. Gastroesophageal reflux disease (GERD). **Mo Med.** 2018;115(3):214–218. Available from: https://pubmed.ncbi.nlm.nih.gov/30228725/
4. Gupta A, Shetty S, Mutalik S, et al. Treatment of H. pylori infection and gastric ulcer: need for novel pharmaceutical formulation. **Heliyon.** 2023;9:e20406. doi:10.1016/j.heliyon.2023.e20406
5. Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. **Ther Adv Gastroenterol.** 2018;11:1756283X17745776. doi:10.1177/1756283X17745776
6. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double-blind study. **Gut.** 2016;65(9):1439–1446. doi:10.1136/gutjnl-2015-311304
7. Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers—are they the next generation of proton pump inhibitors? **World J Gastrointest Pharmacol Ther.** 2018;9(7):63–68. doi:10.4292/wjgpt.v9.i7.63
8. Scarpignato C, Leifke E, Smith N, Mulford DJ, Lahu G, Facius A, Howden CW. A population pharmacokinetic model of vonoprazan: evaluating the effects of race, disease status, and other covariates on exposure. **J Clin Pharmacol.** 2022;62(6):801–811. doi:10.1002/jcph.2019
9. Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. **Clin Transl Gastroenterol.** 2015;6:e94. doi:10.1038/ctg.2015.18
10. Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: a systematic review with meta-analysis. **Medicine (Baltimore).** 2019;98(8):e15860. doi:10.1097/MD.0000000000015860